- February 17, 2026
Ailux Selected for Digital Oral and Poster Presentations at ECCO’26, Highlighting Potential for Novel IBD Treatment
SHANGHAI (CHINA) and SOMERVILLE, MA (US) — February 17, 2026 — Ailux, an AI-native biologics innovator and a subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced that it will present preclinical data from its TL1A/IL-23 bispecific antibody program at the European Crohn’s and Colitis Organisation (ECCO) Congress 2026, taking place February 18-21, 2026 in Stockholm, Sweden.
“Inflammatory bowel disease (IBD) is a chronic disease with complex biology and significant unmet patient need globally. We are rationally exploring the therapeutic synergy of two promising cytokine targets for the treatment of IBD,” said Alex Li, CEO of Ailux.
“Leveraging our AI-guided antibody design platform, we can efficiently uncover unique hits and comprehensively optimize bispecific candidates for desired properties. Our TL1A/IL-23 bispecific antibody demonstrates potent dual-pathway blockade and superior in vivo efficacy in preclinical mouse models. Importantly, our TL1A monoclonal antibody exhibits a potential first-in-class mechanism of action, representing a highly differentiated approach to TL1A blockade.”
The data will be presented on February 20, 2026, at the ECCO Congress as detailed below:
Digital Oral Presentation (DOP) Session 14: Clinical IBD and Novel Targets
Session# DOP122
Time: 18:09 – 18:15
Guided Poster Presentation
Poster# P0122
Time: 12:40 – 13:40
Full session details can be accessed via the official ECCO program.
About Ailux
Ailux is a biologics innovation company dedicated to developing advanced biotherapeutics with AI-powered solutions. As XtalPi’s dedicated biologics platform, Ailux integrates proprietary computational models with state-of-the-art wet lab capabilities to tackle previously undruggable targets and design molecules with novel therapeutic profiles.
With a global team of more than 100 members, Ailux partners with leading biopharmaceutical companies to translate cutting-edge science into transformative medicines.